February 6, 2026
Lir Life Sciences Corp.
ISIN: CA50206C1005
LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Vancouver, Canada – February 5, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company) is pleased to announce that it has...
Read more >>LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Vancouver, Canada – January 29, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce positive interim results...
Read more >LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
Vancouver, Canada – January 22, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce the completion of a study...
Read more >LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
Vancouver, Canada – January 15, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce the launch of...
Read more >LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
Vancouver, Canada – January 8, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has...
Read more >LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Vancouver, Canada – December 18, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that Dr. Peter Singer, a...
Read more >LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
Vancouver, Canada – December 11, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent application...
Read more >Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
Vancouver, Canada – December 10, 2025 – Lir Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new...
Read more >